Jain PharmaBiotech, Feb 2012, Pages: 639
of drug delivery in the management of cancers of the brain, the bladder, the breast, the ovaries and the prostate are used as examples to illustrate different approaches both experimental and clinical
GlobalData, April 2011, Pages: 308
) therapy and mitomycin C are the other drugs that are used for the treatment of bladdercancer.
Gemcitabine was the top-selling drug in the bladdercancer therapeutics market in 2010. The other leading
GlobalData, Dec 2010, Pages: 47
is Urocidin. The drug is currently in Phase III clinical trials for the treatment of non-muscle-invasive bladdercancer patients who did not respond to prior TICE BCG therapy. Urocidin received Special Protocol
Jain PharmaBiotech, Feb 2012, Pages: 1008
by liposuction are also discussed. Stem cells can also be genetically modified prior to transplantation.
Cell therapy technologies overlap with those of gene therapy, cancer vaccines, drug delivery, tissue
GBI Research, Feb 2011, Pages: 209
Area, Global, Early Stage R&D Pipeline by Phase in Myocardial Infarction Therapeutics, December 2010
Table 19: Drug Discovery and Preclinical Molecules by Therapy Area, BladderCancer Therapeutics
GlobalData, Aug 2011, Pages: 119
briefing pertaining to the number of trials for the key drugs for treating BladderCancer. This report is built using data and information sourced from proprietary databases, primary and secondary
Global Industry Analysts, Inc., Oct 2011, Pages: 897
increasing use of these traditional therapies in combination with new cancertherapies, as a means to increase efficacy profiles.
Cancertherapies are treatments indicated for controlling growth of cancerous
Jain PharmaBiotech, Feb 2012, Pages: 864
-1 as a biomarker of gefitinib resistance
Methylation biomarkers of drug resistance in cancer
STAT3 and resistance to cisplatin
Biomarkers of radiation therapy for cancer
Role of biomarkers in drug
Datamonitor, Nov 2008, Pages: 95
. There is therefore a large patient potential for drugs that can replace BCG or treat BCG-refractory patients.
Bladdercancertherapy consists of cytotoxics and immunotherapy agents that have been genericized for many
John Wiley and Sons Ltd, July 2010, Pages: 432
the tremendous potential of microbial and biotechnological approaches to cancertherapy, but also discover new directions of research for effective drug discovery and development. PREFACE
CONTRIBUTORS
PART I
Spectra Intelligence, April 2006, Pages: 369
for Advanced Lung Cancer
Table 3.8 Chemotherapy Drugs Most Commonly Used to Treat Colorectal Cancer
Table 3.9 Breast Cancer Chemotherapy Treatment Options
Table 3.10 Hormonal TherapiesUsed in the Treatment
Global Markets Direct, Dec 2010, Pages: 114
in the therapeutic development for BladderCancer. “BladderCancer-Pipeline Review 2010, Q4 2010” is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University
GBI Research, Feb 2011, Pages: 209
19: Early Stage Drug Discovery in Disease Segments, BladderCancer Therapeutics, Prevalence by Country, 2009 124
Table 20: Early Stage Drug Discovery in Disease Segments, Global, Early Stage R
Bioseeker, Feb 2011
rate is 94%.
There are today 93 (81) companies plus partners developing 104 (86) drugs targeting bladdercancer in development. In addition, there are 2 (4) suspended drugs and the accumulated number
Jain PharmaBiotech, Feb 2012, Pages: 225
and cancer to diagnosis of several other diseases. Other important applications are drug discovery, and development of personalized medicine.
The chapter on markets provides a global perspective
TriMark Publications, July 2011, Pages: 214
Table 2.1: Genes and Cancer Risk 19
Table 2.2: Use of Cancer Biomarkers to Enhance Patient Care 24
Table 2.3: Targeted DrugTherapies for Cancers 24
Table 2.4: Use of Cancer Biomarkers in Drug Development
TriMark Publications, May 2008, Pages: 182
, 2006 61
Table 4.6: Genes and Cancer Risk 62
Table 4.7: Carcinogens in the Workplace 64
Table 5.1: DrugsUsed in BladderCancerTherapy 69
Table 5.2: Drugs in Development for BladderCancer 71
Table 5
Global Markets Direct, Feb 2011, Pages: 116
in the therapeutic development for BladderCancer. 'BladderCancer - Pipeline Review, Q1 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University
